Subscribe To
Relmada and rel-1017: intriguing underlying efficacy in mdd ahead of eventful 2024
Phase 3 trial failures were due to abnormally high placebo responses driven by poor trial design, enrollment, and oversight. REL-1017's underlying eff...
October 13, 2023, 7:50 pm
Apa corporation and totalenergies announce oil project of 200,000 b/d in block 58 and launch development studies with the objective of sanctioning the project by year-end 2024
HOUSTON, Sept. 13, 2023 (GLOBE NEWSWIRE) — APA Corporation (Nasdaq: APA) and TotalEnergies have announced the launching of development studies for a...
September 13, 2023, 7:27 pm
Lanzatech global, inc. announces second quarter 2023 financial results
Operating revenues of $12.9 million for second quarter 2023, an increase of 31% over second quarter 2022 Current cash, restricted cash, and investment...
August 9, 2023, 10:01 am
Angle technology to be used in cancer clinical trial
ANGLE PLC (AIM:AGL, OTCQX:ANPCY), a pioneer of liquid biopsy technology, announced a significant contract win with Artios Pharma. Under the deal ANG...
May 25, 2023, 2:36 am
Liveramp's $1.1 billion buyback authorization: time to get back in
Yesterday, LiveRamp announced it has increased its share buyback authorization by $100 million to $1.1 billion. That made for a nice headline, but let...
December 22, 2022, 1:23 pm
Ecb's villeroy: determined to get inflation down to around 2% by end 2024 or end 2025
- Inflation should peak some time in 1H 2023 and then go down
- ECB will raise rates as much as necessary
- Voted for a 50 bps rate ...
December 16, 2022, 7:20 am
Tg therapeutics: ublituximab could achieve $1 billion in annual sales by year-end 2024
TG Therapeutics is approaching its Prescription Drug User Fee Act (PDUFA) goal date of December 28, 2022, for ublituximab for the treatment of relapsi...
December 15, 2022, 2:04 pm